Qu Biologics Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 50
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $2.2M
Latest Deal Amount
  • Investors
  • 8

Qu Biologics General Information

Description

Developer of site-specific immunotherapy designed to restore the body's normal immune function to treat cancer and other immune-related diseases. The company's immunotherapy utilizes built-in knowledge to direct an activated innate immune response to specific organs or tissues to respond productively to any pathology that may be present at that body site and it contains a single inactivated microbial species that the immune system recognizes as a common cause of infection in a specific organ or tissue, enabling medical researchers to develop a therapy that can activate and train the human immune system to fight cancer and other diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Primary Office
  • 4475 Wayburne Drive
  • Suite 305
  • Burnaby, British Columbia V5G 4X4
  • Canada
+1 (604) 000-0000

Qu Biologics Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Qu Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Grant 23-Jun-2021 $2.2M 000.00 Completed Clinical Trials - Phase 2
10. Later Stage VC 09-Dec-2020 000 000.00 0000 Completed Clinical Trials - Phase 2
9. Later Stage VC 02-Aug-2019 000.00 Completed Generating Revenue
8. Angel (individual) 04-Jun-2018 000.00 000.00 Completed Clinical Trials - Phase 2
7. Angel (individual) 12-Apr-2016 00.000 000.00 Completed Clinical Trials - Phase 2
6. Grant 06-Apr-2016 00000 000.00 Completed Clinical Trials - Phase 2
5. Angel (individual) 23-Dec-2015 00.000 000.00 Completed Generating Revenue
4. Angel (individual) 00.000 000.00 Completed Generating Revenue
3. Angel (individual) 17-Sep-2014 $7.49M $12.4M Completed Generating Revenue
2. Angel (individual) 01-Jun-2012 $4.93M $4.93M Completed Startup
To view Qu Biologics’s complete valuation and funding history, request access »

Qu Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of site-specific immunotherapy designed to restore the body's normal immune function to treat cancer and other
Drug Discovery
Burnaby, Canada
50 As of 2021
000.00
0000000000 000.00

00000000

cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culp
0000 000000000
Rockville, MD
0 As of 0000
000.00
0000000000 0 000.00

00000000

isi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit es
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Qu Biologics Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytImmune Sciences Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00 00000000 Venture Capital-Backed Glasgow, United Kingdom 00 000.00 00000000 000.00
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000 Venture Capital-Backed Cambridge, United Kingdom 00 000.00 00000000000 000.00
You’re viewing 5 of 16 competitors. Get the full list »

Qu Biologics Patents

Qu Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210052645-A1 Innate targeting of adoptive cellular therapies Pending 03-Jan-2018 0000000000000
EP-3735265-A1 Innate targeting of adoptive cellular therapies Pending 03-Jan-2018 0000000000000
CA-3086832-A1 Innate targeting of adoptive cellular therapies Pending 03-Jan-2018 0000000000000
US-20170087237-A1 Anti-microbial immunomodulation Granted 02-May-2014 00000000000 0
US-10251946-B2 Anti-microbial immunomodulation Active 02-May-2014 A61K39/0266 0
To view Qu Biologics’s complete patent history, request access »

Qu Biologics Executive Team (9)

Name Title Board Seat Contact Info
Hal Gunn MD Co-Founder, Chief Executive Officer & Board Member
Rob Freeman Co-Founder
Jim Pankovich Vice President, Clinical Operations & Drug Development
Roderick Campbell Chief Financial Officer
Bob Cory Vice President, Business Development
You’re viewing 5 of 9 executive team members. Get the full list »

Qu Biologics Board Members (6)

Name Representing Role Since
Hal Gunn MD Qu Biologics Co-Founder, Chief Executive Officer & Board Member 000 0000
Julia Levy Ph.D Self Board Member 000 0000
Karn Manhas Qu Biologics Board Member 000 0000
Michael Leschuk Qu Biologics Board Member 000 0000
Robert Pelzer Self Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Qu Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Qu Biologics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
NRC-IRAP Government 000 0000 000000 0
Curitas Ventures Growth/Expansion Minority 000 0000 000000 0
Harmonix Fund Venture Capital Minority 000 0000 000000 0
ACA Investments Asset Manager Majority 000 0000 000000 0
Genome British Columbia Not-For-Profit Venture Capital 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »